• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract: ChAdOx1 nCov-19 AstraZeneca COVID-19 vaccine not effective against B.1.351 variant

byConstance Wu
May 6, 2021
in StudyGraphics
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. The ChAdOx1 nCov-19 (AstraZeneca) vaccine was not effective for the prevention of mild-to-moderate COVID-19 infection caused by the B.1.351 variant. 

2. The ChAdOx1 nCov-19 vaccine was effective against mild-to-moderate non-variant COVID-19 infection after a single injection.

Evidence Rating Level: 1 (Excellent)     

Study Rundown: With the emergence of COVID-19 variants, there is the need to investigate vaccine efficacy in this new context. In a randomized controlled trial from South Africa, researchers compared symptomatic COVID-19 infection rates after administration of the ChAdOx1 nCov-19 vaccine, manufactured by AstraZeneca. The study determined two doses of the vaccine were not effective at preventing mild-to-moderate COVID-19 infection caused by the B.1.351 variant. While no evidence was available for the vaccine’s efficacy against severe B.1.351 infection, this study suggests that second-generation COVID-19 vaccines may be needed to protect against this new variant. This study provides strong justification for using the ChAdOx1 nCov-19 vaccine in populations without the new B.1.351 variant. A major limitation of this study is its inability to establish the efficacy of the vaccine against severe covid-19 infection caused by the B.1.351 variant. Nonetheless, the findings were significant, as the study found that the vaccine is effective against non-variant covid-19 infection.

Click to read the study in the NEJM

Relevant Reading: Safety and efficacy of the ChAdOx1 nCov-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomized controlled trials in Brazil, South Africa, and the UK.

In-Depth [randomized controlled trial]: This multicenter, double-blind, randomized controlled trial enrolled 2,026 patients between June 24 and November 9, 2020. Adults between the ages of 18 and 65 with no or well-managed prior comorbidities were eligible for participation in the trial. Patients with human immunodeficiency virus (HIV), previous COVID-19 infection, a history of anaphylaxis after vaccination, and obesity were excluded from the study. Patients were randomized in 1:1 ratio to receive either the ChAdOx1 nCovid-19 vaccine or placebo, respectively. The primary endpoint was symptomatic COVID-19 infection after two weeks following the second injection confirmed by PCR testing. The study also aimed to investigate the efficacy of the vaccine against the new B.1.351 variant. There were 42 cases of mild and moderate COVID-19 infection confirmed, of which 39 cases were caused by the B.1.351 variant. Vaccine recipients accounted for 19 (2.5%) of these infections, while placebo recipients made up the remaining 23 (3.2%) cases. The study revealed a 75.4% vaccine efficacy (95% confidence interval [CI], 8.7 to 95.5) for the prevention of mild-to-moderate COVID-19 infection caused by non-B.1.351 variant two weeks after just a single injection. However, vaccine efficacy against the B.1.351 variant was determined to be 10.4% (95% CI, -76.8 to 54.8). The study concluded that the ChAdOx1 nCovid-19 vaccine does not protect against mild-to-moderate COVID-19 infection caused by the B.1.351 variant. No conclusion was possible on vaccine prevention of severe COVID-19 infection caused by the B.1.351 variant.

RELATED REPORTS

Unvaccinated status increases risk of long COVID symptoms

The 2 Minute Medicine Podcast Episode 6

The Scan by 2 Minute Medicine®: The Genetics of Alzheimer’s Disease, the Silent Killer, a Holiday Blizzard and an HIV Vaccine on the Horizon

Image: PD

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: astrazenecaB.1.351ChAdOx1 nCoV-19 vaccineCoronavirusSARS-CoV-2vaccinationvaccine
Previous Post

Sonelokimab 120 mg or less showed significant clinical benefit over placebo in patients with plaque psoriasis

Next Post

Coronary microvascular dysfunction demonstrating improvement after surgery for inflammatory bowel disease

RelatedReports

Medical vaccine exemptions increase after elimination of nonmedical exemptions
Infectious Disease

Unvaccinated status increases risk of long COVID symptoms

January 25, 2023
2MM Podcast

The 2 Minute Medicine Podcast Episode 6

January 13, 2023
The Scan by 2 Minute Medicine®:  Ultra-Trail du Mont-Blanc, Taylor Swift, NBA rookie Chet Holmgren and Magic Mushrooms!
The Scan by 2 Minute Medicine®

The Scan by 2 Minute Medicine®: The Genetics of Alzheimer’s Disease, the Silent Killer, a Holiday Blizzard and an HIV Vaccine on the Horizon

January 11, 2023
2 Minute Medicine Rewind November 23 – November 30, 2014
Emergency

Vaccines for Zaire Ebola virus disease are safe and generate an immune response

January 4, 2023
Next Post
Addressing non-obesity related barriers may improve bariatric surgery effectiveness

Coronary microvascular dysfunction demonstrating improvement after surgery for inflammatory bowel disease

#VisualAbstract: Pembrolizumab improves long-term survival in patients with stage III melanoma

#VisualAbstract: Avelumab does not improve outcomes in patients receiving chemoradiotherapy for squamous cell carcinomas of the head and neck

High schoolers use e-cigarettes to vaporize cannabis

Substance use among hospitalized adolescents infrequently documented in electronic health record

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • The Scan by 2 Minute Medicine®: Maternity Leave Left Out, Dry January, A Measles Resurgence, Dr. GPT
  • Former professional football players may be at greater risk of chronic disease
  • Low-dose pirfenidone may be noninferior to standard dosing in patients with idiopathic pulmonary fibrosis
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options